1qpe › Citations

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA
Structure 7 651-61 (1999)
Related entries: 1qpc, 1qpd, 1qpj

Cited: 155 times
EuropePMC logo PMID: 10404594

Abstract

Background

The lymphocyte-specific kinase Lck is a member of the Src family of non-receptor tyrosine kinases. Lck catalyzes the initial phosphorylation of T-cell receptor components that is necessary for signal transduction and T-cell activation. On the basis of both biochemical and genetic studies, Lck is considered an attractive cell-specific target for the design of novel T-cell immunosuppressants. To date, the lack of detailed structural information on the mode of inhibitor binding to Lck has limited the discovery of novel Lck inhibitors.

Results

We report here the high-resolution crystal structures of an activated Lck kinase domain in complex with three structurally distinct ATP-competitive inhibitors: AMP-PNP (a non-selective, non-hydrolyzable ATP analog); staurosporine (a potent but non-selective protein kinase inhibitor); and PP2 (a potent Src family selective protein tyrosine kinase inhibitor). Comparison of these structures reveals subtle but important structural changes at the ATP-binding site. Furthermore, PP2 is found to access a deep, hydrophobic pocket near the ATP-binding cleft of the enzyme; this binding pocket is not occupied by either AMP-PNP or staurosporine.

Conclusion

The potency of staurosporine against Lck derives in part from an induced movement of the glycine-rich loop of the enzyme upon binding of this ligand, which maximizes the van der Waals interactions present in the complex. In contrast, PP2 binds tightly and selectively to Lck and other Src family kinases by making additional contacts in a deep, hydrophobic pocket adjacent to the ATP-binding site; the amino acid composition of this pocket is unique to Src family kinases. The structures of these Lck complexes offer useful structural insights as they demonstrate that kinase selectivity can be achieved with small-molecule inhibitors that exploit subtle topological differences among protein kinases.

Reviews - 1qpe mentioned but not cited (2)

  1. In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Shin WH, Christoffer CW, Kihara D. Methods 131 22-32 (2017)
  2. Structure-based molecular modeling in SAR analysis and lead optimization. Temml V, Kutil Z. Comput Struct Biotechnol J 19 1431-1444 (2021)

Articles - 1qpe mentioned but not cited (16)

  1. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, Xia B, Beglov D, Vajda S. Nat Protoc 10 733-755 (2015)
  2. LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation. Huang B, Schroeder M. BMC Struct Biol 6 19 (2006)
  3. PocketPicker: analysis of ligand binding-sites with shape descriptors. Weisel M, Proschak E, Schneider G. Chem Cent J 1 7 (2007)
  4. Comparative performance of several flexible docking programs and scoring functions: enrichment studies for a diverse set of pharmaceutically relevant targets. Zhou Z, Felts AK, Friesner RA, Levy RM. J Chem Inf Model 47 1599-1608 (2007)
  5. Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL. Sci Signal 8 rs13 (2015)
  6. Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance. Stogios PJ, Spanogiannopoulos P, Evdokimova E, Egorova O, Shakya T, Todorovic N, Capretta A, Wright GD, Savchenko A. Biochem J 454 191-200 (2013)
  7. Crystal Structure of Alcohol Oxidase from Pichia pastoris. Koch C, Neumann P, Valerius O, Feussner I, Ficner R. PLoS One 11 e0149846 (2016)
  8. Structural and functional insights into Mimivirus ORFans. Saini HK, Fischer D. BMC Genomics 8 115 (2007)
  9. Dynamic clustering threshold reduces conformer ensemble size while maintaining a biologically relevant ensemble. Yongye AB, Bender A, Martínez-Mayorga K. J Comput Aided Mol Des 24 675-686 (2010)
  10. Preference of small molecules for local minimum conformations when binding to proteins. Wang Q, Pang YP. PLoS One 2 e820 (2007)
  11. Stochastic algorithm for kinase homology model construction. Rayan A, Noy E, Chema D, Levitzki A, Goldblum A. Curr Med Chem 11 675-692 (2004)
  12. Improving the performance of the PLB index for ligand-binding site prediction using dihedral angles and the solvent-accessible surface area. Cao C, Xu S. Sci Rep 6 33232 (2016)
  13. Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. Chhikara BS, Ashraf S, Mozaffari S, St Jeans N, Mandal D, Tiwari RK, Ul-Haq Z, Parang K. Molecules 25 E2135 (2020)
  14. A new definition and properties of the similarity value between two protein structures. Saberi Fathi SM. J Biol Phys 42 621-636 (2016)
  15. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma. Zhang L, Yang Z, Sang H, Jiang Y, Zhou M, Huang C, Huang C, Wu X, Zhang T, Zhang X, Wan S, Zhang J. J Enzyme Inhib Med Chem 36 1541-1552 (2021)
  16. Network Pharmacology and Molecular Modeling to Elucidate the Potential Mechanism of Neem Oil against Acne vulgaris. Kola-Mustapha AT, Raji MA, Adedeji O, Ambrose GO. Molecules 28 2849 (2023)


Reviews citing this publication (24)

  1. Protein tyrosine kinase structure and function. Hubbard SR, Till JH. Annu Rev Biochem 69 373-398 (2000)
  2. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Druker BJ, Lydon NB. J Clin Invest 105 3-7 (2000)
  3. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Genestra M. Cell Signal 19 1807-1819 (2007)
  4. Magic bullets for protein kinases. Bishop AC, Buzko O, Shokat KM. Trends Cell Biol 11 167-172 (2001)
  5. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Sánchez C, Méndez C, Salas JA. Nat Prod Rep 23 1007-1045 (2006)
  6. Tyrphostins and other tyrosine kinase inhibitors. Levitzki A, Mishani E. Annu Rev Biochem 75 93-109 (2006)
  7. IRAK-4 inhibitors for inflammation. Wang Z, Wesche H, Stevens T, Walker N, Yeh WC. Curr Top Med Chem 9 724-737 (2009)
  8. Structural aspects of protein kinase control-role of conformational flexibility. Engh RA, Bossemeyer D. Pharmacol Ther 93 99-111 (2002)
  9. The genesis of high-throughput structure-based drug discovery using protein crystallography. Kuhn P, Wilson K, Patch MG, Stevens RC. Curr Opin Chem Biol 6 704-710 (2002)
  10. ATP site-directed competitive and irreversible inhibitors of protein kinases. García-Echeverría C, Traxler P, Evans DB. Med Res Rev 20 28-57 (2000)
  11. Structural biology in drug design: selective protein kinase inhibitors. Scapin G. Drug Discov Today 7 601-611 (2002)
  12. The current status of drug discovery against the human kinome. Eglen RM, Reisine T. Assay Drug Dev Technol 7 22-43 (2009)
  13. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Bahia MS, Kaur M, Silakari P, Silakari O. Cell Signal 27 1039-1055 (2015)
  14. Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. Breen ME, Soellner MB. ACS Chem Biol 10 175-189 (2015)
  15. Src inhibitors: genomics to therapeutics. Sawyer T, Boyce B, Dalgarno D, Iuliucci J. Expert Opin Investig Drugs 10 1327-1344 (2001)
  16. Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability. Prien O. Chembiochem 6 500-505 (2005)
  17. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A, Cleasby A, Jhoti H. Chembiochem 6 506-512 (2005)
  18. The target discovery process. Egner U, Krätzschmar J, Kreft B, Pohlenz HD, Schneider M. Chembiochem 6 468-479 (2005)
  19. Molecular interdiction of Src-family kinase signaling in hematopoietic cells. Geahlen RL, Handley MD, Harrison ML. Oncogene 23 8024-8032 (2004)
  20. Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. Bagley MC, Davis T, Murziani PG, Widdowson CS, Kipling D. Pharmaceuticals (Basel) 3 1842-1872 (2010)
  21. Large crystal growth by thermal control allows combined X-ray and neutron crystallographic studies to elucidate the protonation states in Aspergillus flavus urate oxidase. Oksanen E, Blakeley MP, Bonneté F, Dauvergne MT, Dauvergne F, Budayova-Spano M. J R Soc Interface 6 Suppl 5 S599-610 (2009)
  22. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights. Elkamhawy A, Ali EMH, Lee K. J Enzyme Inhib Med Chem 36 1574-1602 (2021)
  23. Update on lymphocyte specific kinase inhibitors: a patent survey. Martin MW, Machacek MR. Expert Opin Ther Pat 20 1573-1593 (2010)
  24. Regulating the discriminatory response to antigen by T-cell receptor. Gangopadhyay K, Roy S, Sen Gupta S, Chandradasan AC, Chowdhury S, Das R. Biosci Rep 42 BSR20212012 (2022)

Articles citing this publication (113)

  1. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. Mol Cell 6 909-919 (2000)
  2. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Cancer Cell 11 217-227 (2007)
  3. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. ChemMedChem 2 58-61 (2007)
  4. Structural basis for the autoinhibition of focal adhesion kinase. Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, Eck MJ. Cell 129 1177-1187 (2007)
  5. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Cohen MS, Zhang C, Shokat KM, Taunton J. Science 308 1318-1321 (2005)
  6. Structural basis for selective inhibition of Src family kinases by PP1. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM. Chem Biol 6 671-678 (1999)
  7. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, Kalisz HM, Flocco M. J Mol Biol 333 393-407 (2003)
  8. IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. Xue HH, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, Leonard WJ. Proc Natl Acad Sci U S A 99 13759-13764 (2002)
  9. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Müller-Dieckmann HJ, Nienaber VL, Noland BW, Post K, Rajashankar KR, Ramos A, Russell M, Burley SK, Buchanan SG. J Biol Chem 279 55827-55832 (2004)
  10. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Boggon TJ, Li Y, Manley PW, Eck MJ. Blood 106 996-1002 (2005)
  11. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Zhou YJ, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG, Lin W, Roberts JL, Lengi A, Buckley RH, Geahlen RL, Candotti F, Gadina M, Changelian PS, O'Shea JJ. Mol Cell 8 959-969 (2001)
  12. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP. Structure 14 1835-1844 (2006)
  13. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Smith DG, Buffet M, Fenwick AE, Haigh D, Ife RJ, Saunders M, Slingsby BP, Stacey R, Ward RW. Bioorg Med Chem Lett 11 635-639 (2001)
  14. Structural basis for the recognition of c-Src by its inactivator Csk. Levinson NM, Seeliger MA, Cole PA, Kuriyan J. Cell 134 124-134 (2008)
  15. Stretch of beta 1 integrin activates an outwardly rectifying chloride current via FAK and Src in rabbit ventricular myocytes. Browe DM, Baumgarten CM. J Gen Physiol 122 689-702 (2003)
  16. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Leukemia 27 48-55 (2013)
  17. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Biochem J 375 255-262 (2003)
  18. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV. Chem Biol 10 705-712 (2003)
  19. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Mol Cell Proteomics 3 490-500 (2004)
  20. Insights into regulation of human Schwann cell proliferation by Erk1/2 via a MEK-independent and p56Lck-dependent pathway from leprosy bacilli. Tapinos N, Rambukkana A. Proc Natl Acad Sci U S A 102 9188-9193 (2005)
  21. Structural and functional characterization of the human protein kinase ASK1. Bunkoczi G, Salah E, Filippakopoulos P, Fedorov O, Müller S, Sobott F, Parker SA, Zhang H, Min W, Turk BE, Knapp S. Structure 15 1215-1226 (2007)
  22. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Zheng Y, Fang YC, Li J. Oncol Lett 18 5399-5407 (2019)
  23. Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8. Jia SH, Parodo J, Kapus A, Rotstein OD, Marshall JC. J Biol Chem 283 5402-5413 (2008)
  24. The pp60c-Src inhibitor PP1 is non-competitive against ATP. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. FEBS Lett 537 47-52 (2003)
  25. An electrostatic selection mechanism controls sequential kinase signaling downstream of the T cell receptor. Shah NH, Wang Q, Yan Q, Karandur D, Kadlecek TA, Fallahee IR, Russ WP, Ranganathan R, Weiss A, Kuriyan J. Elife 5 e20105 (2016)
  26. Trafficking of Lyn through the Golgi caveolin involves the charged residues on alphaE and alphaI helices in the kinase domain. Kasahara K, Nakayama Y, Ikeda K, Fukushima Y, Matsuda D, Horimoto S, Yamaguchi N. J Cell Biol 165 641-652 (2004)
  27. Conformational transitions upon ligand binding: holo-structure prediction from apo conformations. Seeliger D, de Groot BL. PLoS Comput Biol 6 e1000634 (2010)
  28. Src kinase activation: A switched electrostatic network. Ozkirimli E, Post CB. Protein Sci 15 1051-1062 (2006)
  29. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Li L, Hisamoto K, Kim KH, Haynes MP, Bauer PM, Sanjay A, Collinge M, Baron R, Sessa WC, Bender JR. Proc Natl Acad Sci U S A 104 16468-16473 (2007)
  30. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. Davies TG, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CC, McHardy T, Collins I, Garrett MD, Workman P, Woodhead SJ, Jhoti H, Barford D. J Mol Biol 367 882-894 (2007)
  31. Sequence and structural analysis of kinase ATP pocket residues. Vulpetti A, Bosotti R. Farmaco 59 759-765 (2004)
  32. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Jacobs MD, Caron PR, Hare BJ. Proteins 70 1451-1460 (2008)
  33. Crystal structures of active SRC kinase domain complexes. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, Koch S, Schäfer W, Huber R, Engh RA. J Mol Biol 353 222-231 (2005)
  34. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, Rafferty P, Ratnofsky SE. Bioorg Med Chem Lett 10 2167-2170 (2000)
  35. Which electrospray-based ionization method best reflects protein-ligand interactions found in solution? a comparison of ESI, nanoESI, and ESSI for the determination of dissociation constants with mass spectrometry. Jecklin MC, Touboul D, Bovet C, Wortmann A, Zenobi R. J Am Soc Mass Spectrom 19 332-343 (2008)
  36. Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen. Shah NH, Löbel M, Weiss A, Kuriyan J. Elife 7 e35190 (2018)
  37. Alternative binding modes of an inhibitor to two different kinases. De Moliner E, Brown NR, Johnson LN. Eur J Biochem 270 3174-3181 (2003)
  38. Can MM-PBSA calculations predict the specificities of protein kinase inhibitors? Page CS, Bates PA. J Comput Chem 27 1990-2007 (2006)
  39. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Giannini A, Bijlmakers MJ. Mol Cell Biol 24 5667-5676 (2004)
  40. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors. Das J, Moquin RV, Lin J, Liu C, Doweyko AM, DeFex HF, Fang Q, Pang S, Pitt S, Shen DR, Schieven GL, Barrish JC, Wityak J. Bioorg Med Chem Lett 13 2587-2590 (2003)
  41. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T. Chem Biol Drug Des 67 46-57 (2006)
  42. Structure of human Fyn kinase domain complexed with staurosporine. Kinoshita T, Matsubara M, Ishiguro H, Okita K, Tada T. Biochem Biophys Res Commun 346 840-844 (2006)
  43. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Gazit A, Yee K, Uecker A, Böhmer FD, Sjöblom T, Ostman A, Waltenberger J, Golomb G, Banai S, Heinrich MC, Levitzki A. Bioorg Med Chem 11 2007-2018 (2003)
  44. Aurora-A recruitment and centrosomal maturation are regulated by a Golgi-activated pool of Src during G2. Barretta ML, Spano D, D'Ambrosio C, Cervigni RI, Scaloni A, Corda D, Colanzi A. Nat Commun 7 11727 (2016)
  45. PKC-dependent activation of FAK and src induces tyrosine phosphorylation of Cas and formation of Cas-Crk complexes. Bruce-Staskal PJ, Bouton AH. Exp Cell Res 264 296-306 (2001)
  46. Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. Zhang X, Arnott JA, Rehman S, Delong WG, Sanjay A, Safadi FF, Popoff SN. J Cell Physiol 224 691-701 (2010)
  47. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Burchat AF, Calderwood DJ, Hirst GC, Holman NJ, Johnston DN, Munschauer R, Rafferty P, Tometzki GB. Bioorg Med Chem Lett 10 2171-2174 (2000)
  48. ROS-dependent activation of RhoA/Rho-kinase in pulmonary artery: Role of Src-family kinases and ARHGEF1. MacKay CE, Shaifta Y, Snetkov VV, Francois AA, Ward JPT, Knock GA. Free Radic Biol Med 110 316-331 (2017)
  49. Amyloid precursor protein mediates a tyrosine kinase-dependent activation response in endothelial cells. Austin SA, Sens MA, Combs CK. J Neurosci 29 14451-14462 (2009)
  50. Modified AutoDock for accurate docking of protein kinase inhibitors. Buzko OV, Bishop AC, Shokat KM. J Comput Aided Mol Des 16 113-127 (2002)
  51. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, Batalov S, Liu Y, Warmuth M, Wiltshire T, Cooke MP, Sauer K. Mol Cell 33 43-52 (2009)
  52. Distinct roles of cellular Lck and p80 proteins in herpesvirus saimiri Tip function on lipid rafts. Park J, Cho NH, Choi JK, Feng P, Choe J, Jung JU. J Virol 77 9041-9051 (2003)
  53. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Furet P, Bold G, Hofmann F, Manley P, Meyer T, Altmann KH. Bioorg Med Chem Lett 13 2967-2971 (2003)
  54. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117. Das J, Lin J, Moquin RV, Shen Z, Spergel SH, Wityak J, Doweyko AM, DeFex HF, Fang Q, Pang S, Pitt S, Shen DR, Schieven GL, Barrish JC. Bioorg Med Chem Lett 13 2145-2149 (2003)
  55. Nonredundant roles of Src-family kinases and Syk in the initiation of B-cell antigen receptor signaling. Stepanek O, Draber P, Drobek A, Horejsi V, Brdicka T. J Immunol 190 1807-1818 (2013)
  56. The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. Gassel M, Breitenlechner CB, König N, Huber R, Engh RA, Bossemeyer D. J Biol Chem 279 23679-23690 (2004)
  57. Chemical genetics identifies c-Src as an activator of primitive ectoderm formation in murine embryonic stem cells. Meyn MA, Smithgall TE. Sci Signal 2 ra64 (2009)
  58. Epidermal Growth Factor Receptor and Abl2 Kinase Regulate Distinct Steps of Human Papillomavirus 16 Endocytosis. Bannach C, Brinkert P, Kühling L, Greune L, Schmidt MA, Schelhaas M. J Virol 94 e02143-19 (2020)
  59. Epidermal growth factor receptor tyrosine kinase regulates the human inward rectifier potassium K(IR)2.3 channel, stably expressed in HEK 293 cells. Zhang DY, Zhang YH, Sun HY, Lau CP, Li GR. Br J Pharmacol 164 1469-1478 (2011)
  60. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bamborough P, Angell RM, Bhamra I, Brown D, Bull J, Christopher JA, Cooper AW, Fazal LH, Giordano I, Hind L, Patel VK, Ranshaw LE, Sims MJ, Skone PA, Smith KJ, Vickerstaff E, Washington M. Bioorg Med Chem Lett 17 4363-4368 (2007)
  61. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck). Sabat M, VanRens JC, Laufersweiler MJ, Brugel TA, Maier J, Golebiowski A, De B, Easwaran V, Hsieh LC, Walter RL, Mekel MJ, Evdokimov A, Janusz MJ. Bioorg Med Chem Lett 16 5973-5977 (2006)
  62. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Miyazawa K, Misawa K, Ohnota H, Isaji M. Bioorg Med Chem 16 7347-7357 (2008)
  63. Down-regulation of cell surface CXCR6 expression during T cell activation is predominantly mediated by calcineurin. Koprak S, Matheravidathu S, Springer M, Gould S, Dumont FJ. Cell Immunol 223 1-12 (2003)
  64. Quercetin stimulates Na+/K+/2Cl- cotransport via PTK-dependent mechanisms in human airway epithelium. Asano J, Niisato N, Nakajima K, Miyazaki H, Yasuda M, Iwasaki Y, Hama T, Dejima K, Hisa Y, Marunaka Y. Am J Respir Cell Mol Biol 41 688-695 (2009)
  65. S1PR1 Tyr143 phosphorylation downregulates endothelial cell surface S1PR1 expression and responsiveness. Chavez A, Schmidt TT, Yazbeck P, Rajput C, Desai B, Sukriti S, Giantsos-Adams K, Knezevic N, Malik AB, Mehta D. J Cell Sci 128 878-887 (2015)
  66. Structural model for p75(NTR)-TrkA intracellular domain interaction: a combined FRET and bioinformatics study. Iacaruso MF, Galli S, Martí M, Villalta JI, Estrin DA, Jares-Erijman EA, Pietrasanta LI. J Mol Biol 414 681-698 (2011)
  67. Comparative analysis of mutant tyrosine kinase chemical rescue. Muratore KE, Seeliger MA, Wang Z, Fomina D, Neiswinger J, Havranek JJ, Baker D, Kuriyan J, Cole PA. Biochemistry 48 3378-3386 (2009)
  68. Relative contributions of desolvation, inter- and intramolecular interactions to binding affinity in protein kinase systems. Sims PA, Wong CF, Vuga D, McCammon JA, Sefton BM. J Comput Chem 26 668-681 (2005)
  69. 3D structural analysis of protein O-mannosyl kinase, POMK, a causative gene product of dystroglycanopathy. Nagae M, Mishra SK, Neyazaki M, Oi R, Ikeda A, Matsugaki N, Akashi S, Manya H, Mizuno M, Yagi H, Kato K, Senda T, Endo T, Nogi T, Yamaguchi Y. Genes Cells 22 348-359 (2017)
  70. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). Wityak J, Das J, Moquin RV, Shen Z, Lin J, Chen P, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, Schieven GL, Kanner SB, Barrish JC. Bioorg Med Chem Lett 13 4007-4010 (2003)
  71. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M. Bioorg Med Chem 16 9247-9260 (2008)
  72. X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase. Muckelbauer J, Sack JS, Ahmed N, Burke J, Chang CY, Gao M, Tino J, Xie D, Tebben AJ. Chem Biol Drug Des 78 739-748 (2011)
  73. Protein tyrosine kinase signaling is necessary for NO donor-induced late preconditioning against myocardial stunning. Tang XL, Kodani E, Takano H, Hill M, Shinmura K, Vondriska TM, Ping P, Bolli R. Am J Physiol Heart Circ Physiol 284 H1441-8 (2003)
  74. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC. Oncogene 28 518-533 (2009)
  75. Genistein and tyrphostin AG556 inhibit inwardly-rectifying Kir2.1 channels expressed in HEK 293 cells via protein tyrosine kinase inhibition. Zhang DY, Wu W, Deng XL, Lau CP, Li GR. Biochim Biophys Acta 1808 1993-1999 (2011)
  76. Macrophages Respond Rapidly to Ototoxic Injury of Lateral Line Hair Cells but Are Not Required for Hair Cell Regeneration. Warchol ME, Schrader A, Sheets L. Front Cell Neurosci 14 613246 (2020)
  77. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. Zhou T, Commodore L, Huang WS, Wang Y, Sawyer TK, Shakespeare WC, Clackson T, Zhu X, Dalgarno DC. Chem Biol Drug Des 75 18-28 (2010)
  78. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Miyazawa K, Misawa K, Ohnota H, Isaji M. Bioorg Med Chem 17 284-294 (2009)
  79. Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. Munoz L, Kavanagh ME, Phoa AF, Heng B, Dzamko N, Chen EJ, Doddareddy MR, Guillemin GJ, Kassiou M. Eur J Med Chem 95 29-34 (2015)
  80. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Kumar A, Wang Y, Lin X, Sun G, Parang K. ChemMedChem 2 1346-1360 (2007)
  81. Development of a HTRF kinase assay for determination of Syk activity. Harbert C, Marshall J, Soh S, Steger K. Curr Chem Genomics 1 20-26 (2008)
  82. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Chen P, Norris D, Das J, Spergel SH, Wityak J, Leith L, Zhao R, Chen BC, Pitt S, Pang S, Shen DR, Zhang R, De Fex HF, Doweyko AM, McIntyre KW, Shuster DJ, Behnia K, Schieven GL, Barrish JC. Bioorg Med Chem Lett 14 6061-6066 (2004)
  83. Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF. Kiley SC, Chevalier RL. Am J Physiol Renal Physiol 293 F895-903 (2007)
  84. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck). Chen P, Norris D, Iwanowicz EJ, Spergel SH, Lin J, Gu HH, Shen Z, Wityak J, Lin TA, Pang S, De Fex HF, Pitt S, Shen DR, Doweyko AM, Bassolino DA, Roberge JY, Poss MA, Chen BC, Schieven GL, Barrish JC. Bioorg Med Chem Lett 12 1361-1364 (2002)
  85. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors. Shen L, Prouty C, Conway BR, Westover L, Xu JZ, Look RA, Chen X, Beavers MP, Roberts J, Murray WV, Demarest KT, Kuo GH. Bioorg Med Chem 12 1239-1255 (2004)
  86. Phosphorylation of human enhancer of filamentation (HEF1) on serine 369 induces its proteasomal degradation. Hivert V, Pierre J, Raingeaud J. Biochem Pharmacol 78 1017-1025 (2009)
  87. Structure determination of human Lck unique and SH3 domains by nuclear magnetic resonance spectroscopy. Briese L, Willbold D. BMC Struct Biol 3 3 (2003)
  88. Two Methods, One Goal: Structural Differences between Cocrystallization and Crystal Soaking to Discover Ligand Binding Poses. Wienen-Schmidt B, Oebbeke M, Ngo K, Heine A, Klebe G. ChemMedChem 16 292-300 (2021)
  89. Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60(c-Src) tyrosine kinase inhibitors. Olgen S, Isgör YG, Coban T. Arch Pharm (Weinheim) 341 113-120 (2008)
  90. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). Sabat M, Vanrens JC, Brugel TA, Maier J, Laufersweiler MJ, Golebiowski A, De B, Easwaran V, Hsieh LC, Rosegen J, Berberich S, Suchanek E, Janusz MJ. Bioorg Med Chem Lett 16 4257-4261 (2006)
  91. Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field. Papageorgiou C, Camenisch G, Borer X. Bioorg Med Chem Lett 11 1549-1552 (2001)
  92. Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates. Martínez-Mármol R, Small C, Jiang A, Palliyaguru T, Wallis TP, Gormal RS, Sibarita JB, Götz J, Meunier FA. Mol Psychiatry 28 946-962 (2023)
  93. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer. Dey G, Bharti R, Braley C, Alluri R, Esakov E, Crean-Tate K, McCrae K, Joehlin-Price A, Rose PG, Lathia J, Gong Z, Reizes O. J Ovarian Res 16 122 (2023)
  94. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors. Dincer S, Cetin KT, Onay-Besikci A, Ölgen S. J Enzyme Inhib Med Chem 28 1080-1087 (2013)
  95. The role of Src kinase in the biology and pathogenesis of Acanthamoeba castellanii. Siddiqui R, Iqbal J, Maugueret MJ, Khan NA. Parasit Vectors 5 112 (2012)
  96. A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation. Lui VG, Hoenig M, Cabrera-Martinez B, Baxter RM, Garcia-Perez JE, Bailey O, Acharya A, Lundquist K, Capera J, Matusewicz P, Hartl FA, D'Abramo M, Alba J, Jacobsen EM, Niewolik D, Lorenz M, Pannicke U, Schulz AS, Debatin KM, Schamel WW, Minguet S, Gumbart JC, Dustin ML, Cambier JC, Schwarz K, Hsieh EWY. J Exp Med 221 e20230927 (2024)
  97. Crystal structure of the MAP3K TAO2 kinase domain bound by an inhibitor staurosporine. Zhou TJ, Sun LG, Gao Y, Goldsmith EJ. Acta Biochim Biophys Sin (Shanghai) 38 385-392 (2006)
  98. Evaluation of new indole and bromoindole derivatives as pp60(c-Src) tyrosine kinase inhibitors. Kiliç Z, Işgör YG, Olgen S. Chem Biol Drug Des 74 397-404 (2009)
  99. Geldanamycin, a heat-shock protein 90-binding agent, induces thymocyte apoptosis through destabilization of Lck in presence of 12-O-tetradecanoylphorbol 13-acetate. Ohta K, Okoshi R, Wakabayashi M, Ishikawa A, Sato Y, Kizaki H. Biomed Res 28 33-42 (2007)
  100. Structural basis for the inhibitor recognition of human Lyn kinase domain. Miyano N, Kinoshita T, Nakai R, Kirii Y, Yokota K, Tada T. Bioorg Med Chem Lett 19 6557-6560 (2009)
  101. Auto-thiophosphorylation activity of Src tyrosine kinase. Cabail MZ, Chen EI, Koller A, Miller WT. BMC Biochem 17 13 (2016)
  102. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase. Awale M, Mohan CG. J Mol Model 14 937-947 (2008)
  103. Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-beta receptor (PDGFbeta R) inhibitors, derived from molecular modeling. Mori Y, Hirokawa T, Aoki K, Satomi H, Takeda S, Aburada M, Miyamoto K. Chem Pharm Bull (Tokyo) 56 682-687 (2008)
  104. Mechanisms determining a differential threshold for sensing Src family kinase activity by B and T cell antigen receptors. Borna S, Fabisik M, Ilievova K, Dvoracek T, Brdicka T. J Biol Chem 295 12935-12945 (2020)
  105. One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities. Rao VK, Chhikara BS, Tiwari R, Shirazi AN, Parang K, Kumar A. Bioorg Med Chem Lett 22 410-414 (2012)
  106. Comparison of some 3-(substituted-benzylidene)-1,3-dihydroindolin derivatives as ligands of tyrosine kinase based on binding mode studies and biological assay. Olgen S. Arch Pharm Res 29 1006-1017 (2006)
  107. Letter Sequence-specific 1H, 13C and 15N resonance assignments of lymphocyte specific kinase unique and SH3 domains. Briese L, Hoffmann S, Friedrich U, Biesinger B, Willbold D. J Biomol NMR 19 193-194 (2001)
  108. Src tyrosine kinases contribute to serotonin-mediated contraction by regulating calcium-dependent pathways in rat skeletal muscle arteries. Zavaritskaya O, Lubomirov LT, Altay S, Schubert R. Pflugers Arch 469 767-777 (2017)
  109. Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5. Kiliç Z, Isgör YG, Olgen S. Arch Pharm (Weinheim) 342 333-343 (2009)
  110. Novel inhibitors of microtubule organization and phragmoplast formation in diverse plant species. Kimata Y, Yamada M, Murata T, Kuwata K, Sato A, Suzuki T, Kurihara D, Hasebe M, Higashiyama T, Ueda M. Life Sci Alliance 6 e202201657 (2023)
  111. A novel member of lymphocyte-specific protein tyrosine kinase protein identified in lamprey, Lampetra japonica. Han Y, Liu X, Dai P, Zhao C, Li T, Wang J, Xiao R, Li Q. Acta Biochim Biophys Sin (Shanghai) 46 820-825 (2014)
  112. Configurational stability of bisindolylmaleimide cyclophanes: from conformers to the first configurationally stable, atropisomeric bisindolylmaleimides. Barrett S, Bartlett S, Bolt A, Ironmonger A, Joce C, Nelson A, Woodhall T. Chemistry 11 6277-6285 (2005)
  113. Hypoglycemic Activity of Rice Resistant-Starch Metabolites: A Mechanistic Network Pharmacology and In Vitro Approach. Ren J, Dai J, Chen Y, Wang Z, Sha R, Mao J, Mao Y. Metabolites 14 224 (2024)


Quick links